Brief: Metacrine Achieves Enrollment Target For MET642 Phase 2A Trial Interim Analysis
18/05/2021 13:48
May 18 (Reuters) - Metacrine Inc. MTCR.O :
* METACRINE ACHIEVES ENROLLMENT TARGET FOR MET642 PHASE 2A
TRIAL
INTERIM ANALYSIS
* METACRINE, INC. - INTERIM DATA FROM FIRST 60 PATIENTS WITH
NASH
ON TRACK TO BE REPORTED IN Q4 OF 2021
* METACRINE, INC. - ENROLLMENT CONTINUING FOR UP TO 180
PATIENTS,
WITH FULL TOPLINE RESULTS EXPECTED TO BE REPORTED IN FIRST HALF
OF 2022
Source text for Eikon: ID:nGNX9RyYpj
Further company coverage: MTCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions